Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor...
Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor...
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in...
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in...
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”),...
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”),...
Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical ProgressNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) --...
Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical ProgressNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) --...
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE...
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE...
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug...
"With rising demand across pharma, electronics, and automotive sectors, contract manufacturing offers cost savings, supply chain stability, and access to...
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Aug. 12, 2025 /PRNewswire/ -- USA News...
A new standard in GLP-1 therapy that individualizes dosing and patient care for better results, with potentially fewer side effects,...
The company, which has a waitlist of more than 32,000, is now available in California, with plans to expand into...
ST. PETERSBURG, Fla., Aug. 12, 2025 /PRNewswire/ -- Cognitive Research Corporation (CRC), a full-service CRO specializing in neuroscience, has officially...
Nearly 70% say reducing manual processes is a key priority for working with sites PLEASANTON, Calif., Aug. 12, 2025 /PRNewswire/...
Calgary, Alberta--(Newsfile Corp. - August 12, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it...